4:27 PM
Nov 14, 2017
 |  BC Extra  |  Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing, neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are underwriting the offering.

Denali’s lead candidates include leucine-rich repeat kinase 2 (LRRK2) inhibitors DNL201 and DNL151, and receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitor DNL747.

Parkinson’s disease candidate DNL201 is in a...

Read the full 311 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >